Genetically downregulated SGLT2 signaling and genetically lowered CETP activity are associated with additively lower lifetime risk of metabolic outcomes by way of significantly decreased glycated hemoglobin levels and lower incidence of type-2 diabetes. The gene discussed is CETP; the disease is type 2 diabetes mellitus.